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Alzheimer's disease (AD) is a neurodegenerative disorder of complex etiology, 
with insidious progression and fatal consequences. Its global incidence rates are very 
high, rising in line with the aging population. AD is manifested as a progressive decline 
of cognitive and intellectual functions. Histopathological hallmarks include the presence 
of β-amyloid neuritic plaques, neurofibrillary tangles composed of hyperphosphorylated 
τ protein and atrophy of brain tissue. Neurotransmitter levels are decreased in case 
of acetylcholine (ACh) while glutamate levels are elevated. Nowadays, there are two 
pharmacological groups employed in the treatment of AD: acetylcholinesterase inhibitors 
(AChEIs) and antagonist of N-methyl-D-aspartate receptors (NMDARs) – memantine. 
Both groups act only symptomatically, not having disease-modifying effect. The aim 
of our study was preparation of a series of novel hybrid molecules combining AChEIs, 
namely tacrine, 7-methoxytacrine and 6-chlorotacrine, with molecule BQCA – positive 
allosteric modulator of M1 subtype of muscarinic ACh receptors (mAChRs). Inhibitory 
effectiveness of the newly synthetized compounds against cholinesterases (ChEs) was 
determined in vitro by the Ellman´s colorimetric method and expressed as IC50. The effect 
on mAChRs was determined by measurement of intracellular calcium concentration 
using fluorescent indicator. The results proved the ability of newly synthesized molecules 
to inhibit ChEs in the micromolar and sub-micromolar IC50 values, with antagonist 
activity towards M1 mAChRs. 
 
